Regencell Bioscience Investors Face Class Action After DOJ Probe

Regencell Bioscience Holdings Limited saw its market valuation reach $14 billion despite reporting zero revenue, a staff of twelve, and minimal annual research spending. Shares that traded below $0.30 for much of the period surged to $78.00 in June 2025, only to collapse following the disclosure of a U.S. Department of Justice subpoena in October. The pending litigation alleges that the company issued materially misleading statements that downplayed market manipulation risks and attributed extreme volatility to external factors rather than internal business performance.

Fiduciaries and pension fund managers now face potential exposure regarding their stewardship of these assets. The lawsuit, filed under the Securities Exchange Act of 1934, claims that the company’s public filings failed to disclose the true nature of its exposure to governmental scrutiny. For institutional holders, the deadline to apply for lead plaintiff status—a role that allows for direct oversight of litigation strategy—is June 23, 2026. Legal counsel Joseph E. Levi noted that institutional participation is essential for the rigorous monitoring of such complex proceedings, particularly given that the court typically favors movants with the largest documented financial interests.